OR-502 is under clinical development by OncoResponse and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According to GlobalData, Phase II drugs for Cutaneous Squamous Cell Carcinoma (cSCC) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OR-502’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OR-502 overview

OR-502 is under development for the treatment of melanoma, sarcoma, cutaneous squamous cell carcinoma (CSCC), ovarian cancer. The drug candidate is fully humanized monoclonal antibody and is being developed based on Theraclone's I-STAR technology platform. It acts by targeting LILRB2 (leukocyte immunoglobulin-like receptor subfamily B member 2). It is administered through intravenous route.

OncoResponse overview

OncoResponse is an immuno-oncology company. It discovers, develops and commercializes novel antibodies against cancer by using a human antibody platform. The company’s pipeline products include OR2805 a reprogrammed tumor-associated macrophage and myeloid-derived suppressor cell; OR641 inhibits myeloid and lymphoid checkpoint; OR502 acts as reverse immunosuppression and reprograms tumor-associated macrophage; TME 2.0 is interrogate B-cell repertoire for mAb candidates. It works in partnership with MD Anderson Cancer Center and Theraclone Sciences. OncoResponse is headquartered in Seattle, Washington, the US.

For a complete picture of OR-502’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.